Summit Therapeutics

Summit Therapeutics 今日大幅低开，盘中一度跌至 13.43 美元，较前收盘 14.98 美元下跌逾 10%，主要因公司宣布启动一项高达 3.8 亿美元的市价股权发行计划（ATM）并披露二季度净亏损达 2.157 亿美元。盘前交易中股价已低至 13.71 美元，日内高点 14.40 美元出现在盘前时段，常规交易时段未能收复失地，最终收于 13.95 美元。此次融资压力叠加亏损扩大（Q1 净亏损 1.894 亿美元，同比扩大 201%），令市场担忧其现金消耗速度。不过，公司核心管线 ivonescimab 已获 FDA 突破性疗法认定并进入 III 期，近期公布的总生存期数据积极，部分抵消了抛压。当前股价较 52 周高点 30.98 美元深跌 55%，且低于 20 日均线 14.807 美元和 60 日均线 15.722 美元，YTD 跌幅达 20.38%。

Summit Therapeutics shares rose over 5% in regular trading, driven by a confluence of recent positive catalysts: the co-CEO's insider purchase of over $49 million in stock and the withdrawal of a proposed public offering last week, which alleviated dilution concerns. Additionally, partner Akeso's HARMONi-6 trial in China showed ivonescimab plus chemotherapy achieved a statistically significant overall survival benefit versus tislelizumab plus chemotherapy in first-line squamous NSCLC, bolstering the core pipeline's profile. However, at $14.19, the stock remains 54% below its 52-week high of $30.98 and trades below both its 20-day ($14.74) and 60-day ($16.08) moving averages. The company's Q1 net loss widened to $189 million with no revenue, underscoring the fundamental challenges.

Summit Therapeutics experienced a sharp intraday decline, trading at $14.295 as of 10:25 ET, down 5.14% from the prior close. The drop was primarily driven by the company's withdrawal of its proposed public offering (id:289461120) and mixed market reactions to competitor data. The stock opened at $14.900 and fell steadily to an intraday low of $14.295, with volume around 409k shares and a turnover rate of 0.3%. While the co-CEO's insider purchase of over $49 million (id:289622557) had previously boosted sentiment, Q1 earnings showed a net loss of $189.4 million, widening 201% YoY, with no revenue. The stock is now 53.9% below its 52-week high of $30.98 and trading below both the 20-day MA ($14.792) and 60-day MA ($16.615), with a YTD decline of 18.4%. However, post-market activity showed a slight recovery to $15.120, suggesting some bargain buying.

SMMT 今日盘中强势单边上行，截至 ET09:43 报 15.100 美元，涨幅 5.01%，主因近期多项临床试验数据持续释放积极信号。盘前价格从 14.410 美元起步，早盘低探 14.380 美元后快速拉起，盘中最高触及 15.100 美元，振幅达 4.99%，成交量 17.16 万股，显著高于近期日均。昨日盘后报价 14.420 美元，已预示买盘意愿。此前 HARMONi-6 研究显示伊沃西单抗联合化疗对比替雷利珠单抗联合化疗在鳞状 NSCLC 一线治疗中取得统计显著的总生存期获益，同时结直肠癌全球 II 期数据在 ASCO 2026 上亦有积极表现，叠加高管近期斥资逾 4900 万美元增持，强化市场信心。不过当前股价距 52 周高点 30.98 美元仍腰斩达-51.26%，且市盈率-9.72 倍、市净率 21.47 倍，反映盈利基础缺失。